EMA Authorised: Edarbi (azilsartan medoxomil) — Takeda Pharma A/S

View source ↗

Summary

The European Medicines Agency authorised Edarbi (azilsartan medoxomil) for hypertension; Takeda Pharma A/S is the marketing authorisation holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• Edarbi (azilsartan medoxomil)

Snippet

Status: Authorised. Therapeutic area: Hypertension. MAH: Takeda Pharma A/S. Decision date: 29/01/2025